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Abstract
Background: Many new treatments for degeneration of the intervertebral disc are being
developed which can be delivered through a needle. These require testing in model systems before
being used in human patients. Unfortunately, because of differences in anatomy, there are no ideal
animal models of disc degeneration. Bovine explant model systems have many advantages but it is
not possible to inject any significant volume into an intact disc. Therefore we have attempted to
mimic disc degeneration in an explant bovine model via enzymatic digestion.
Methods: Bovine coccygeal discs were incubated with different concentrations of the proteolytic
enzymes, trypsin and papain, and maintained in culture for up to 3 weeks. A radio-opaque solution
was injected to visualise cavities generated. Degenerative features were monitored histologically
and biochemically (water and glycosaminoglycan content, via dimethylmethylene blue).
Results and Conclusion: The central region of both papain and trypsin treated discs was macro-
and microscopically fragmented, with severe loss of metachromasia. The integrity of the
surrounding tissue was mostly in tact with cells in the outer annulus appearing viable. Biochemical
analysis demonstrated greatly reduced glycosaminoglycan content in these compared to untreated
discs. We have shown that bovine coccygeal discs, treated with proteolytic enzymes can provide a
useful in vitro model system for developing and testing potential new treatments of disc
degeneration, such as injectable implants or biological therapies.
Background
There is currently a great deal of interest in developing
new therapies to address degeneration of the interverte-
bral disc, due to the association of disc degeneration with
low back pain. These therapies range from injectable syn-
thetic nucleus replacements to biological approaches such
as cell therapy [1,2]. Before being used in humans, any
potential new therapies should be tested in model sys-
tems, either in vitro or in vivo. Animal models of disc
degeneration are limited, with no ideal model [3]. Small
animals such as rodents or rabbits have a different cell
type and anatomy from that found in humans and large
animals are expensive, do not develop the same pattern of
degeneration as in humans, and some of these also have a
different cell type.
Bovine caudal discs have been developed as a suitable
model for many in vitro studies of the intervertebral disc,
having similar physico-chemical properties to the human
disc [4]. However, these bovine discs have such a high
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swelling-pressure that it is virtually impossible to inject
any significant volume into them, thus they cannot be
used for testing nuclear replacements unless they are mod-
ified. In this paper we describe a technique for developing
an explant model of disc degeneration in the bovine cau-
dal disc that would be suitable for testing injectable
nucleus pulposus replacements. We have characterised
the properties of the disc following enzymatic digestion
which results in some similar changes as are seen in
degeneration of the human intervertebral disc. This high-
lights its potential uses and limitations for testing novel
therapeutic developments for degenerative intervertebral
discs.
Methods
(i) Samples
Bovine tails were obtained from animals aged 18–30
months at a local abattoir within 1 hour of death. Before
dissection tails were washed in 500 parts per million of
chlorine to minimise risk of infection. Skin was removed
and motion segments, 1.5 to 2 cm in diameter, were dis-
sected from the tail, under sterile conditions. They were
cleaned of soft tissues, including muscles and ligaments.
The segments were washed thoroughly with sterile phos-
phate buffered saline (PBS, Invitrogen, Paisley) before
washing for 10 minutes with standard culture medium
(Dulbecco's modified Eagles medium (DMEM:F12, Invit-
rogen) supplemented with 500 μg/ml ascorbic acid
(Sigma), 10% foetal bovine serum (PAA Laboratories,
Yeovil), 0.05% Gentamicin (Invitrogen) and 0.005% Fun-
gizone (Invitrogen)). Thirty eight motion segments (1.5–
2.3 cm in diameter, mean 1.8 cm ± 0.3) were obtained
from the central region of tails from approximately 12
animals.
(ii) Enzyme Digestion
For induction of degeneration of the nucleus pulposus,
motion segments were injected with i) 20 mg/ml of
papain (18 U/mg protein, Sigma) in buffer (0.01 M
cysteine hydrochloride, 0.5 mM EDTA, 0.2 M sodium ace-
tate, pH 6), ii) trypsin, used at 1, 5, 10 or 20 mg/ml trypsin
in PBS (12,400 U/mg protein Sigma), or iii) untreated,
with nothing injected (as 'controls'). It was difficult to be
accurate in recording the exact volume injected, due to
subsequent back pressure but it was estimated that 70–
100 μl was used per treatment. Motion segments were cul-
tured in standard culture medium at 37°C in a 5%CO2
humidified atmosphere. At day 1 the action of the trypsin
was stopped by injection with FBS; the medium was
changed on all the motion segments at day 1 and then
every 3 or 4 days. Three samples (randomised from differ-
ent animals) for each treatment were harvested at 1, 2 and
3 weeks at which time they were X-rayed, cut in half sagit-
tally and photographed. One half was processed for his-
tology and the other was used for biochemical
assessment. In addition 3 untreated discs were excised and
analysed similarly to provide control baseline values
('normals').
The disc dimensions (circumference, diameter and
height) were measured in a separate sample of 8 motion
segments before (V0) and after (V1) digestion with papain
for one week. These measurements were used to make an
estimate of disc volume. Disc volume used to give an indi-
cation of the degree of swelling which might occur during
the incubation.
(iii) Radiography and histology
Intact motion segments were injected with a radio-opaque
solution (Omnipaque, Amersham, Buckinghamshire)
before X-raying (32 kV for 80 seconds exposure) and then
dissected using a band saw. The volume injected was
recorded. One half of the motion segment was fixed in
formol saline for 24 hours before transferring to decalcify-
ing solution (10% formic acid in formalin) for 1–2 weeks
until decalcification was complete (as assessed with radi-
ographs). Samples were then embedded in paraffin wax
and 4 μ thick sections were cut and stained with either
haematoxylin and eosin (H&E) or toluidine blue [5].
Morphology was assessed by standard light microscopy
using both bright and polarised light.
(iv) Biochemical assessment
Bone was removed from the cranial and caudal aspects of
the remaining half motion segment. The central half of
the disc was cut into 2 columns, which were then cut into
approximately 1 mm thick slices from the outer annulus,
through to the mid nucleus to provide a profile of gly-
cosaminoglycan (GAG) and water contents. The pre-
weighed slices of disc were dried to a constant weight at
60°C and the water content calculated as percentage of
total wet weight.
The dried disc slices were then digested with 1 ml papain
solution (2.5 mg of papain in 20 ml of 0.01 M cysteine
hydrochloride, 0.5 mM EDTA, 0.2 M sodium acetate, pH
6) at 60°C for 4 hours. The GAG content was measured
using a dimethylmethylene blue (DMB (Serva)) assay [6],
modified to a 96 well plate method.
Results
(i) Morphology
Macroscopic changes to the structure of the enzyme
treated discs were visible by the naked eye on dissection of
the motion segments (Figure 1). The integrity of the con-
trol discs appeared intact at all time points; in contrast, all
enzyme treated discs had cavities in the centre. This alter-
ation was restricted to the nucleus pulposus for trypsin
treated discs at all time points and at weeks 1 and 2 for
papain-treated. At 3 weeks after papain injection, how-
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ever, the disruption extended into the annulus for all sam-
ples so treated. Radiograph imaging of motion segments
injected with radio-opaque dye demonstrate that the
amount which could be injected into the centre of the disc
increased with the amount of enzyme used (Figure 2),
occupying approximately 10–25% of the disc volume
after a week.
These changes were also seen microscopically with central
fissures seen clearly on all enzyme treated discs (Figure
3a). There were obviously no cells within the nuclear
region which was digested, but in the surrounding matrix
the cells were generally healthy in appearance (though no
cell viability measurements were made) and occurring at
a similar density as in the controls. Toluidine blue stained
sections of untreated control discs demonstrated some
loss of metachromasia, particularly in the outer annulus.
However, sections of enzyme treated discs, both those
treated with papain and trypsin, showed severe and much
greater loss of metachromasia at all time points (Figure
3b). Control discs, incubated for 3 weeks had little meta-
chromasia in the outer annulus; this pattern is similar to
that of normal, freshly obtained discs, reflecting the lower
GAG content found in this region. Blood vessels were seen
in the outer annulus fibrosus of both enzyme treated and
untreated discs. The morphology of these, the cells within
them and the disc cells themselves appeared normal, even
after 3 weeks of incubation (Figure 4).
The dimensions of the motion segments changed little
during the enzymatic digestion and incubation. The orig-
inal estimated volume of the disc (V0) was 1.10 ± 0.17 cm
whereas 1 week later (V1) it was 1.11 ± 0.16 cm (n = 8).
The volume which could be injected was 136 ± 44 μl (n =
8), ie 12% of the volume of the disc.
(ii) Biochemistry
The water and GAG contents of untreated, fresh (normal)
bovine discs was similar to the control discs and, as
reported many times previously, higher in the central
nucleus pulposus than in the annulus fibrosus. Profiles of
water content showed no significant difference from those
in any of the discs which had been enzymatically digested
(at any time points; Figure 5). The profiles of GAG con-
tents, in contrast, were much lower for both enzymes
used, but were particularly reduced for papain treated
discs, which all had a GAG content lower than 10% CS/
dry weight (compared to 15–30% of normal discs in the
nucleus). Trypsin treated discs reached this level 2 weeks
after the enzyme had been introduced.
(a) H&E stained sections at 3 weeks post-incubation with 20 mg trypsin, 20 mg papain or no enzyme (control)Fi ure 3
(a) H&E stained sections at 3 weeks post-incubation with 20 
mg trypsin, 20 mg papain or no enzyme (control). (b) Toluid-
ine blue stained sections demonstrating severe loss of meta-
chromasia from all of the disc in enzyme treated discs 
compared to non-enzymatically digested, where loss is dimin-
ished and only in the outer annulus.
Trypsin Papain Controla
b Trypsin Papain control
Macroscopic appearance of dissected motion segments after incubation for 1 week with 20 mg/ml of trypsin, papain or noenzyme (control)Figur 1
Macroscopic appearance of dissected motion segments after 
incubation for 1 week with 20 mg/ml of trypsin, papain or no 
enzyme (control).
Radiographic images of motion segments injected with radio-opaque mediu  72 h urs after incubation with 1, 5 or 10 mg/ml trypsinFi ur 2
Radiographic images of motion segments injected with radio-
opaque medium 72 hours after incubation with 1, 5 or 10 
mg/ml trypsin.
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Discussion
Any new therapy developed for the treatment of interver-
tebral disc degeneration to alleviate or delay the onset of
associated back pain must go through the inevitable series
of testing prior to human trials. Models of disc degenera-
tion have severe limitations [3] with none providing the
ideal test environment. Certain properties, for example
cytotoxicity, can be carried out on cell cultures. However,
disc cells isolated from their extracellular matrix have a
completely different morphology and size than when
retained within it [7], such that explant models are more
likely to reflect the in vivo situation than isolated cell mod-
els. Whilst the use of explant models will not preclude the
complete use of whole animal in vivo models, they may be
able to answer many of the questions which have to be
asked and minimise the number and hence reduce the
investment in cost and ethics otherwise required to take a
new product to clinical trials and the marketplace.
There are already several in vitro models described in the
literature which, although they are characterised by addi-
tional techniques (eg cell number and viability, immuno-
histochemistry, qRT-PCR) to those used in this study,
many involve small species, for example mouse [8], rat
[9,10] or rabbit [11]. These species have inherent limita-
tions of size and notochordal cells within the nucleus pul-
posus region. More recently larger discs from bigger
animals such as sheep and cattle have been cultured as
explant models with the possibility of studying mecha-
nisms of disc degeneration [12,13]. Likewise several mod-
els have utilised enzyme digestion of the extracellular
matrix (summarised in reviews [4,14]. Many of these were
developed to mimic and understand better the physiolog-
ical response to the treatment of chemonucleolysis. More
recently there is renewed interest in this as a clinical treat-
ment, with chondroitinase ABC as an alternative enzyme.
Imai et al [15] use this in a rabbit model of chemonucle-
olysis, whilst it has also been suggested to be useful for a
model of degeneration in mice[16]. Antoniou et al [17]
have used different enzymes to examine the effect of deg-
radation of individual matrix components (for example,
collagen or proteoglycans) on magnetic resonance imag-
ing parameters. Little has been detailed, however, on the
GAG profile, which is probably the most important bio-
chemical parameter relating to disc degeneration.
There are real physical limitations of injecting any signifi-
cant volume into a healthy disc (though small volumes
such as might be used for testing growth factor or even cell
therapy can obviously be introduced). In contrast, in the
clinical setting where it is envisaged that newly designed
implants might be injected into a degenerate human lum-
bar intervertebral disc, it can often be easy to inject vol-
umes of at least 2 ml of a substance (i.e. approximately
10% of its volume). Hence there is a requirement for a
model system of a degenerate disc which is larger than the
animal discs most commonly used in such tests and
H&E stained sections of the annulus of discs showing blood vessels (arrows) and disc c lls 2 weeks after incubationFigure 4
H&E stained sections of the annulus of discs showing blood 
vessels (arrows) and disc cells 2 weeks after incubation. (a) 
control discs (×40 mag.), (b) trypsin treated (×40 mag.) and 
(c) trypsin treated at higher magnification (×250).
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which has properties more similar to those of the human
disc. The bovine coccygeal disc provides such samples,
with similar properties in terms of composition, swelling
pressure and metabolism to those seen in human discs
[4]. We have shown in this study that breakdown and loss
of GAGs can be induced, sufficient to inject a potential
nuclear replacement for subsequent testing. (Several
nuclear replacements are being investigated by other
groups, for example, NuCore® Injectable Nucleus (Spine
Wave Inc, Shelton, CT, USA) and the BioDisc™ (Cryolife
Inc, Kennesaw, GA, USA)).
There have been some studies examining explant culture
with and without the vertebral endplates attached, indi-
cating that bovine discs without endplates and ovine with
endplates could maintain viability for up to 1 week
[12,13]. The vertebral bone (and ligamentous tissue) cer-
tainly seemed to be an advantage in the present study in
that swelling was severely restricted, with no significant or
obvious swelling of the whole motion segment, although
it is likely that the similar water content seen in the treated
and control discs was due to lack of restraint against swell-
ing via musculature, ligaments etc such as would occur in
The profile from outer annulus to the central nucleus pulposus of (a) water and (b) GAG contents of fresh normal, bovine disc (i.e. not injected with enzyme or cultur d)Figure 5
The profile from outer annulus to the central nucleus pulposus of (a) water and (b) GAG contents of fresh normal, bovine disc 
(i.e. not injected with enzyme or cultured).
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vivo. In addition, the enzymes used to treat the motion
segments did not appear to have affected the histology of
the remaining surrounding tissue greatly or any differ-
ently from that seen in the untreated controls. Both
trypsin and papain created a 'space' allowing material to
be injected, but trypsin may be preferable on a cost-basis
and is certainly much cheaper than other enzymes such as
chymopapain or collagenase. Likewise, there was little dif-
ference between time-points studied, particularly for
papain, hence this would be recommended to use for the
shortest interval.
This model could have several uses for testing newly
developed products. These could include application sys-
tems, mechanical properties of implants or their adhesive
and interaction properties. Indeed, preliminary data has
been obtained with this model, whereby an injectable gel
has been inserted and tested under either hydrostatic load
(approximately 4 kg for 2 hrs) or cyclic loading (4 kg, 600
cycles at a frequency of 1 Hz; Dr S Sarit, personal commu-
nication). In addition to testing implants, they could also
be used to assess biological approaches and, for example,
monitor injected cells. When developing new therapies,
the choice of the ideal test system depends very much on
the questions being asked. In this study we have shown
that the use of a general proteolytic enzyme together with
a bovine coccygeal explant system can provide a means of
producing a cheap, reproducible system suitable for test-
ing some of the new generation of injectable implants
which are being developed in the spine field.
Conclusion
Several injectable novel therapies are being developed
worldwide for treating degeneration of the intervertebral
disc associated with back pain. As with all such develop-
ments these require testing and evaluation in the labora-
tory prior to taking to the clinic. Unfortunately 'normal'
discs have a high swelling pressure and resist injecting any
volume of substance into. Hence we have developed an
explant model which mimics some aspects of disc degen-
eration and would be suitable for testing the new genera-
tion of injectable therapies for treating degenerate discs in
humans.
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